Skip to main content

Day: December 24, 2019

Goliath Closes $50,000 Non-Brokered Private Placement of Flow-Through Funding

NOT FOR DISSEMINATION IN THE UNITED STATESTORONTO, Dec. 24, 2019 (GLOBE NEWSWIRE) — Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (FSE: B4IE) (the “Company or “Goliath”) announces an additional non-brokered private placement of $50,000 has closed in flow-through financing for a total of $550,000 in flow-through funding raised since November 1, 2019 (see news release).This offering consisted of One Million (1,000,000) flow-through shares priced at $0.05 each and no finders’ fees were paid. It is subject to the final approval of the TSX Venture Exchange, and all shares issued pursuant to the offering will be subject to a statutory hold period of four-months plus one day from the date of closing.About GoliathGoliath Resources Limited is a project generator of precious metals projects focused...

Continue reading

DÉCLARATION DES TRANSACTIONS SUR ACTIONS PROPRES RÉALISÉES DU 17 DÉCEMBRE AU 19 DÉCEMBRE 2019

CommuniquéDÉCLARATION DES TRANSACTIONS SUR ACTIONS PROPRES RÉALISÉESDU 17 DÉCEMBRE AU 19 DÉCEMBRE 2019Paris – 24 décembre 2019Dans le cadre de l’exécution de son programme de rachat d’actions annoncée par communiqué du 06 février 2019, le prestataire de service d’investissement mandaté par Klépierre a réalisé les transactions résumées dans le tableau qui suit entre le 17 décembre et le 19 décembre 2019 :

Continue reading

DISCLOSURE OF TRADING IN OWN SHARES FROM DECEMBER 17, 2019 TO DECEMBER 19, 2019

RELEASEDISCLOSURE OF TRADING IN OWN SHARES FROM DECEMBER 17, 2019 TO DECEMBER 19, 2019Paris – December 24, 2019As announced in a press release dated February 06, 2019, Klépierre mandated an investment services provider to repurchase its own shares. The following table sums up the buyback transactions carried out by said provider between December 17 and December 19, 2019:

Continue reading

Information regarding the voting rights and shares

24 December 2019Information regarding the voting rights and shares(Article L.233-8-II of the French Commercial Codeand 223-16 of the General Regulations of the “AMF”)Listing location: NYSE Euronext-ParisCompartiment: Eurolist AISIN code: FR 0010242511*Number of exercisable voting rights = Number of theoretical voting rights (or total number of voting rights calculated on the basis of all shares to which voting rights are attached) – number of shares without voting rights.AttachmentPR_Information_regarding_the_voting_rights_and_number_of_shares

Continue reading

Information relative au nombre total de droits de vote et d’actions composant le capital social

           Le 24 décembre 2019                                                                Information relative au nombre total de droits de vote et d’actions composant le capital social(Article L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’AMF)Place de cotation :       NYSE Euronext-ParisCode ISIN :                 ...

Continue reading

Santa Fe Gold Appoints Daniel E. Gorski, Geologist / Technical Advisor for Exploration, Development and Mining for Santa Fe Gold, To Its Board of Directors

ALBUQUERQUE, N.M., Dec. 24, 2019 (GLOBE NEWSWIRE) — Santa Fe Gold Corporation, (SFEG) OTC, a U.S. based mining company that currently ranks 9th out of the top ten US based mid-tier and junior precious metals companies (as cited by prestigious mining industry trade journal, The Northern Miner), with 148 mining claims covering 42 mine sites is pleased to announce with immediate effect, the appointment to its Board of Directors of Santa Fe Gold, its Geologist / Technical Advisor for Exploration, Development and Mining, Daniel E. Gorski.Mr. Gorski has served as geologist / technical advisor to Santa Fe Gold, since November 2018, and currently also serves as President and CEO of Texas Minerals Resources Corporation, TMRC.Daniel Gorski was appointed President and Chief Executive Officer of Texas Minerals Resources Corporation...

Continue reading

Philips completes cancellation of 8.54 million shares

December 24, 2019Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it has completed the cancellation of 8,541,356 of its shares. The cancelled shares were acquired as part of Philips’ EUR 1.5 billion share repurchase program that started in the first quarter of 2019. Further details on the repurchase program can be found here. Philips’ current issued share capital amounts to EUR 179,346,744.20 representing 896,733,721 common shares.For further information, please contact:Steve KlinkPhilips Global Press OfficeTel.: +31 6 10888824E-mail: steve.klink@philips.comKsenija GonciarenkoPhilips Investor RelationsTel.: +31 20 5977055E-mail: ksenija.gonciarenko@philips.comAbout Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s...

Continue reading

Abeona Therapeutics reçoit la désignation PRIME de l’Agence européenne des médicaments pour la thérapie génique ABO-102 pour le traitement du MPS IIIA

NEW YORK et CLEVELAND, 24 déc. 2019 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq : ABEO), un leader pleinement intégré en thérapie génique et cellulaire, a annoncé aujourd’hui que l’Agence européenne des médicaments (EMA) a accordé la désignation de Médicament prioritaire (PRIME) au programme ABO-102 de la société, qui étudie sa thérapie génique ponctuelle à base de virus adéno-associé 9 (AAV9) pour le traitement de la maladie de Sanfilippo de type A (MPS IIIA). La désignation PRIME repose sur des données cliniques et non cliniques issues de l’étude Transpher A, un essai clinique mondial de phase 1/2 évaluant une dose unique d’ABO-102...

Continue reading

Abeona Therapeutics erhält PRIME-Status der Europäischen Arzneimittelagentur für ABO-102 Gentherapie bei MPS IIIA

NEW YORK und CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), ein vollständig integrierter Marktführer im Bereich der Gen- und Zelltherapie, hat heute bekanntgegeben, dass die Europäische Arzneimittelagentur (EMA) dem ABO-102-Programm des Unternehmens, im Rahmen dessen die Adeno-assoziierte Virus 9(AAV9)-Gentherapie bei Sanfilippo-Syndrom Typ A (MPS IIIA) untersucht wird, den PRIME-Status für unentbehrliche Medikamente verliehen hat. DerPRIME-Status basiert auf nichtklinischen Daten und klinischen Daten aus der Transpher A-Studie, einer weltweit durchgeführten klinischen Studie der Phase I/II, in der eine Einzeldosis von ABO-102 zur Behandlung von Kindern mit MPS IIIA untersucht wird.„Der PRIME-Status der EMA für das ABO-102-Programm erkennt die dringende Notwendigkeit...

Continue reading

Veritas Farms CEO Alexander Salgado to Appear on Yahoo Finance This Morning, Tuesday, December 24, 2019

Fort Lauderdale, FL, Dec. 24, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Veritas Farms, Inc. (OTCQB: VFRM) (“Veritas Farms” or the “Company”), a vertically integrated agribusiness focused on the production of full spectrum hemp oil products with naturally occurring cannabinoids, is pleased to announce that its CEO, Alexander M. Salgado, will appear this morning on Yahoo Finance’s “On The Move with Adam Shapiro and Julie Hyman,” broadcasting live from 11:00 a.m. to 1:00 p.m. ET.Alexander M. Salgado, CEO and co-founder of Veritas Farms, commented, “The opportunity to discuss Veritas Farms’ recent expansions on a globally streamed business program like Yahoo Finance will put the Veritas Farms™ brand in front of a large audience of potential new customers and investors,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.